Literature DB >> 19479188

The association between high VEGF levels and multiple probable punctuate cavernous malformations.

Tatsuya Abe1, M Morishige, H Ooba, T Kamida, M Fujiki, H Kobayashi, T Sakoda, Y Kimba.   

Abstract

Cerebral cavernous malformations (CCMs) are congenital abnormalities of the cerebral vessels. The de novo development of new lesions in this disease has been reported. However, the underlying mechanism of progressive CCMs in such patients remains unclear. This report documents two cases of multiple probable CCMs that showed a progressive behaviour. The plasma levels of vascular endothelial growth factor (VEGF), and transforming growth factor-beta1 (TGF-beta1) were measured using an enzyme-linked immunosorbent assay (ELISA). The concentration of both VEGF and TGF-beta1 in plasma was increased in these patients. A relationship was observed between high concentrations of growth factors and progressive CCMs. Even though a causal linkage between these conditions cannot be confirmed, a continuous high VEGF level in plasma could be a possible clinical indicator for subsequent intracerebral haemorrhages in the CCM patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479188     DOI: 10.1007/s00701-009-0410-6

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  10 in total

1.  Chronic encapsulated intracerebral hematoma associated with cavernous malformation.

Authors:  Satoru Takeuchi; Kojiro Wada; Fumihiro Sakakibara; Kentaro Mori
Journal:  J Korean Neurosurg Soc       Date:  2014-02-28

2.  Gyrate: CCM3 dances with a different angiogenic partner.

Authors:  Laura A Dyer; Andrea L Portbury; Cam Patterson
Journal:  Sci Signal       Date:  2010-05-18       Impact factor: 8.192

3.  Multiple cavernous malformations with hemorrhage of brain.

Authors:  Rajniti Prasad; Sujoy Saha; Om Prakash Mishra; Arvind Srivastava
Journal:  Indian J Pediatr       Date:  2014-03-06       Impact factor: 1.967

4.  Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years.

Authors:  W Brinjikji; V N Iyer; V Yamaki; G Lanzino; H J Cloft; K R Thielen; K L Swanson; C P Wood
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-24       Impact factor: 3.825

5.  KRIT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signaling.

Authors:  Peter V DiStefano; Julia M Kuebel; Ingrid H Sarelius; Angela J Glading
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

Review 6.  Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype.

Authors:  Aubrey C Chan; Dean Y Li; Michel J Berg; Kevin J Whitehead
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

Review 7.  Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin.

Authors:  Saverio Francesco Retta; Angela J Glading
Journal:  Int J Biochem Cell Biol       Date:  2016-09-14       Impact factor: 5.085

8.  VEGF signalling enhances lesion burden in KRIT1 deficient mice.

Authors:  Peter V DiStefano; Angela J Glading
Journal:  J Cell Mol Med       Date:  2019-11-20       Impact factor: 5.310

9.  Simplex cerebral cavernous malformations with MAP3K3 mutation have distinct clinical characteristics.

Authors:  Ran Huo; Jie Wang; Ying-Fan Sun; Jian-Cong Weng; Hao Li; Yu-Ming Jiao; Hong-Yuan Xu; Jun-Ze Zhang; Shao-Zhi Zhao; Qi-Heng He; Shuo Wang; Ji-Zong Zhao; Yong Cao
Journal:  Front Neurol       Date:  2022-08-26       Impact factor: 4.086

10.  Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.

Authors:  Miguel Alejandro Lopez-Ramirez; Catherine Chinhchu Lai; Shady Ibrahim Soliman; Preston Hale; Angela Pham; Esau J Estrada; Sara McCurdy; Romuald Girard; Riya Verma; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Robert Shenkar; Orit Poulsen; Gabriel G Haddad; Richard Daneman; Brendan Gongol; Hao Sun; Frederic Lagarrigue; Issam A Awad; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.